Indian Pricing Watchdog NPPA Turns Down Requests For Insulin Price Hike; Lilly Moves To Court
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Several global pharmaceutical firms are heading for a collision with India's National Pharmaceutical Pricing Authority after the drug price regulator turned down their requests for an upward price revision of leading imported brands